#Japan #Tokyo #Gene Editing #KII #One Genomics

Advancing Gene Editing: KII's Investment in One Genomics

In a significant move towards enhancing gene editing technology, Keio Innovation Initiative (KII) has made an investment in One Genomics, a startup emerging from Kyushu University. Based in San Francisco, One Genomics is at the forefront of research in gene therapy, particularly through its innovative Safeguard gRNA Technology. This funding marks a pivotal point in their mission to accelerate research and development while also expanding their customer outreach within Japan.

Understanding One Genomics’ Vision

Founded in February 2023 by CEO Diana Luan, One Genomics is focused on harnessing and advancing gene editing efficiencies. The company's ambitious aim is to enhance both the safety and effectiveness of these technologies by over 100 times. Traditional methods, such as the CRISPR-Cas system, have been popular due to their simplicity; however, they often face challenges related to unintended genetic mutations and cellular toxicity. As the medical field increasingly relies on these techniques, the call for improved methodologies to address safety and efficacy concerns has become louder.

The Role of Safeguard gRNA Technology

One Genomics' Safeguard gRNA Technology goes beyond conventional CRISPR methods by allowing for greater flexibility in controlling various editing tools, such as the Cas9 system and Base editor. This advancement ensures that the efficiency and safety of editing induced pluripotent stem (iPS) cells are maximized. The potential of this technology positions it as a potential golden standard in the world of gene editing, aspiring to provide safe and effective gene therapies to the global market.

Commitment to Safe Gene Therapy

The focus of One Genomics is not merely on the scientific advancements but also on real-world applications of their discoveries. By addressing safety issues associated with gene editing, especially in clinical trials, they aim to cultivate trust and acceptance in medical applications. The company's vision emphasizes the importance of a thorough understanding of gene therapy's potential risks and ensuring that, as this field progresses, it can do so without compromising patient safety.

KII’s Mission and Impact

The KII was founded in December 2015 with the aim of supporting startups that utilize research outcomes from Keio University. Since January 2020, KII has dedicated itself to not only delivering lead investments from seed and early stages but also driving innovation in society through digital technology and addressing health and medical challenges. Recently, in October 2023, KII established Japan's first impact fund dedicated to academia-based startups, pushing for a society where everyone can live a healthy and happy life. This initiative aligns perfectly with their partnership with One Genomics, providing not just a financial investment but also a shared vision for societal improvement.

Future Perspectives

As One Genomics pushes forward with its revolutionary technology, the collaboration with KII underscores a commitment to innovation in the biotechnology sector. With this partnership, both entities aim to achieve significant milestones in gene therapy and the broader implications of genomic research.

Conclusion

The advancements coming from One Genomics symbolize the next frontier in gene editing technology. With KII's support, their initiatives promise not only to revolutionize medical treatment but also to create measurable social impacts—an essential step towards achieving a healthier global society. For more information on One Genomics, interested parties are encouraged to visit their website at One Genomics.

Company Overview

• - Company Name: One Genomics, Inc.
• - CEO: Diana Luan
• - Established: February 2023
• - Focus: Development of Safeguard gRNA Technology and therapeutic solutions.